Chronic obstructive pulmonary disease: 10 years of precision-guided success

Abstract

The chronic obstructive pulmonary disease (COPD) research community has made substantial progress in the past 10 years. The most important paradigm shifts have been achieved in the prevention, biological assessment, and precision treatment of COPD exacerbations. Exacerbations account for most of the morbidity and mortality in patients with COPD. 1 Instead of accepting these events as inevitable, COPD clinicians now have effective treatments to prevent them. The Informing the Pathway of COPD Treatment (IMPACT) and the Efficacy and Safety of Triple Therapy in Obstructive Lung Disease (ETHOS) studies have found treatments that reduce the frequency of exacerbations and reduce all-cause mortality. In patients with COPD at highest risk of morbidity and mortality, treatments with inhaled corticosteroids (ICS) and maximal bronchodilation save lives.

Document Type

Journal Article

Date of Publication

3-1-2023

Volume

11

Issue

3

PubMed ID

36863785

Publication Title

The Lancet Respiratory Medicine

Publisher

Elsevier

School

School of Medical and Health Sciences

Comments

Ramakrishnan, S. (2023). Chronic obstructive pulmonary disease: 10 years of precision-guided success. The Lancet Respiratory Medicine, 11(3), 227-228. https://doi.org/10.1016/S2213-2600(23)00013-9

Copyright

subscription content

First Page

227

Last Page

228

Link to Full Text

Share

 
COinS
 

Link to publisher version (DOI)

10.1016/S2213-2600(23)00013-9